Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Nam Y. Huh / AP
Medical device company Teleflex is acquiring NeoTract, a smaller company that makes just one medical device, in a deal valued at $1.1 billion. Teleflex will pay $725 million upfront and $375 million in additional payments tied to sales goals.
Why it matters: Teleflex is paying a premium to buy NeoTract's sole product, a urology device that helps treat enlarged prostate glands. But the prostate market is large, profitable and growing. A handful of venture capital firms, including New Enterprise Associates and Questa Capital, poured more than $60 million into NeoTract and are reaping a big payday. Dan Primack reports that this was the result of a dual process by NeoTract, which had confidentially filed for an IPO.
Money talks: "Neotract's Urolift device has strong reimbursement coding and coverage, and (intellectual property) protections run through 2033," Leerink analyst Richard Newitter wrote in an investor note.